Press release
Psoriatic Arthritis Clinical Trial Pipeline Expands as 20+ Pharma Companies Progress 25+ Novel Therapies Toward Market Entry, Finds DelveInsight | Bristol Myers Squibb, Hansoh BioMedical R&D Company and others
Psoriatic Arthritis Pipeline Report
Explore the latest breakthroughs in the Psoriatic Arthritis treatment landscape. Learn more about the evolving Psoriatic Arthritis pipeline today @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Psoriatic Arthritis Pipeline Report
• On 9th March 2026, the FDA approved pharma major Bristol Myers Squibb's (NYSE; BMY) Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for PsA.
• In September 2025, the FDA approved guselkumab (Tremfya) for pediatric PsA - first IL-23 inhibitor approved for children aged ≥6 years (≥40 kg) with active psoriatic arthritis, supported by the Phase 3 PROTOSTAR trial.
• In July 2025, Janssen initiated a Phase 3 study evaluating icotrokinra vs. placebo in active PsA, assessing reduction in signs and symptoms.
• DelveInsight's Psoriatic Arthritis Pipeline Insight report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Psoriatic Arthritis treatment.
• The leading Psoriatic Arthritis companies include Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others.
• Promising Psoriatic Arthritis therapies include Sotyktu (deucravacitinib), HS-10374, si-544 and others.
Download for updates and the latest revolution in Psoriatic Arthritis treatment @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Psoriatic Arthritis Pipeline Report Provides
• Detailed insights about companies developing therapies for Psoriatic Arthritis, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Psoriatic Arthritis treatment.
• Psoriatic Arthritis companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Psoriatic Arthritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Psoriatic Arthritis market.
Learn more about Psoriatic Arthritis Drugs opportunities in our comprehensive Psoriatic Arthritis pipeline report @
https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Psoriatic Arthritis Companies
There are 20+ key companies, such as Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others, developing therapies for Psoriatic Arthritis, with Bristol Myers Squibb having its Psoriatic Arthritis drug candidate in the most advanced Phase III stage.
DelveInsight's Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical
Psoriatic Arthritis products have been categorized under various Molecule types such as:
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Psoriatic Arthritis treatment by visiting our website. Stay informed @
https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Scope of the Psoriatic Arthritis Pipeline Report
• Coverage: Global
• Psoriatic Arthritis companies: Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others
• Psoriatic Arthritis Therapies: Sotyktu (deucravacitinib), HS-10374, si-544 and others.
• Psoriatic Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Psoriatic Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriatic Arthritis Clinical Trial Pipeline Expands as 20+ Pharma Companies Progress 25+ Novel Therapies Toward Market Entry, Finds DelveInsight | Bristol Myers Squibb, Hansoh BioMedical R&D Company and others here
News-ID: 4417687 • Views: …
More Releases from DelveInsight
Acute Myeloid Leukemia Pipeline Insight 2026: 100+ Companies Advancing Novel The …
DelveInsight's "Acute Myeloid Leukemia Pipeline Insight, 2026" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the…
Gastric Cancer Market: HER2+ Segment Valued at USD 700 Million in 2024 Across th …
DelveInsight's "Gastric Cancer Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of gastric cancer epidemiology, market, and clinical development in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Explore the intricate details of the Gastric Cancer Market Report @ https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr
Key Takeaways from Gastric Cancer Market Report
• Gastric cancer represents the fifth most prevalent malignant tumor, with the highest incidence…
End-Stage Renal Disease (ESRD) Market to Witness Significant Growth by 2034, Dri …
DelveInsight's "End-Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of End-Stage Renal Disease, historical and forecasted epidemiology, as well as the End-Stage Renal Disease therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore the intricate details of the End-Stage Renal Disease Market Report @ https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr
Key Takeaways from the End-Stage Renal Disease Market Report
• In September…
Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Forecast to Witness Grow …
DelveInsight's "Non-muscle Invasive Bladder Cancer - Epidemiology Forecast - 2034" report delivers an in-depth understanding of Non-muscle Invasive Bladder Cancer, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Non-Muscle Invasive Bladder Cancer Epidemiology Forecast Report @ https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr
Key Takeaways from the Non-Muscle Invasive Bladder Cancer Epidemiology Report
• In 2023, in the 7MM…
More Releases for Psoriatic
Psoriatic Arthritis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Psoriatic Arthritis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Psoriatic Arthritis Research. Learn more about…
Psoriatic Arthritis Treatment: A New Era of Relief
The Business Research Company recently released a comprehensive report on the Global Psoriatic Arthritis Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The psoriatic arthritis treatment…
Psoriatic Arthritis Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Psoriatic Arthritis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Psoriatic Arthritis Pipeline Report
• Over 20+…
Psoriatic Arthritis Treatment Market - Unleash the Power of Relief: Elevating Tr …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Psoriatic Arthritis Treatment Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Psoriatic Arthritis Treatment provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes…
Psoriatic Arthritis Treatment Market Size, CAGR | Growth - 2030
Exclusive Report by Ameco Research: Psoriatic Arthritis Treatment Market Size Projected to Reach USD 26 Billion by 2030, Growing at 9.60% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Psoriatic Arthritis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality…
Psoriatic Arthritis Treatment Market Growth Framework 2025
Global Psoriatic Arthritis Treatment Market: Overview
The demand within the global psoriatic arthritis treatment market has been rising on account of advancements in the field of healthcare and biosimilar analysis. The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called…
